Quantum Biopharma Ltd (QNTM) Stock Price, Quote & News

Company Profile

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. It operates through two segments, Biopharmaceutical Innovation and Strategic Investments. The company researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. Its lead compound is Lucid-MS, a patented new chemical entity that is...

Industry: Biotechnology

Sector: Healthcare

Phone: 833 571 1811

Website: www.quantumbiopharma.com

Address:

55 University Avenue, Suite 1003, Toronto, Canada

Cons228 Apr. 2 at 8:28 PM

$QNTM thank you, shorts, for confirming that the latest developments in the lawsuit will be massive trouble for you

0 · Reply

focafoca99 Apr. 2 at 7:53 PM

$QNTM says a federal court largely denied the defendants' joint motion to dismiss its $700 million market-manipulation case against CIBC and RBC.

0 · Reply

DzNutz68 Apr. 2 at 2:38 PM

$QNTM these guys shilling are caught short. Fun to watch the panic.

0 · Reply

Rambler1111 Apr. 2 at 1:46 PM

$QNTM

0 · Reply

FickleFin Apr. 2 at 1:25 PM

$QNTM all speculation. All paid bots. Majority of accounts pumping arent real. One person. Multiple accounts. This press release just means: *The lawsuit is still ongoing and not yet won; the legal process could be lengthy, expensive, and the final outcome remains uncertain. Even if Quantum BioPharma prevails, the actual awarded damages may be significantly less than the claimed $700,000,000.

1 · Reply

TheRealBullz Apr. 2 at 1:03 PM

$RY $CM $QNTM https://www.globenewswire.com/news-release/2026/04/02/3267341/0/en/Quantum-BioPharma-Wins-Significant-Court-Challenge-in-USD-700-000-000-Claim-as-Defendants-Joint-Motion-to-Dismiss-Lawsuit-Alleging-Market-Manipulation-by-CIBC-World-Markets-and-RBC.html

1 · Reply

Stock_Catcher Apr. 2 at 12:30 PM

$QNTM Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied

0 · Reply

FickleFin Apr. 2 at 11:21 AM

$QNTM $GNS $GME 🤦🤦🤦

1 · Reply

FickleFin Apr. 2 at 11:19 AM

$QNTM $GNS $GME - UNBUZZD EARNINGS RELEASE APRIL 2026 *Revenue over past 6 months = $3,239 *Revenue over past 3 months = $1,300 INCEPTION was August 2024. Do the Math. THE MATH aint MATHING...🤡 You could invest in their $5,000 minimum investment. 🥴🤬 Guaranteed you wont see a return. They OWE shareholders $$$ from their spinoff shares that still havent come to fruition yet from years ago... 📉

0 · Reply

DzNutz68 Apr. 2 at 3:59 AM

$QNTM 💪💪💪💪👍👍👍👍👍🔥🔥🔥🔥🔥lets go

0 · Reply

Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis

Mon, 30 Mar 2026 07:50:00 -0400 - 4 days ago

Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis

Fri, 27 Mar 2026 19:30:00 -0400 - 6 days ago

Quantum Biopharma Provides Corporate Update

Fri, 27 Mar 2026 08:10:00 -0400 - 7 days ago

Quantum Biopharma's 2025 Audited Year End Financial Results Maintain ‘No Going Concern' Status

Mon, 23 Mar 2026 08:24:00 -0400 - 11 days ago

Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd

Fri, 20 Mar 2026 19:35:00 -0400 - 13 days ago

Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering

Wed, 11 Mar 2026 19:55:00 -0400 - 22 days ago

Quantum BioPharma Provides Corporate Update

Thu, 19 Feb 2026 19:29:00 -0500 - 6 weeks ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM

Thu, 19 Feb 2026 12:00:00 -0500 - 6 weeks ago

Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

Tue, 17 Feb 2026 13:55:00 -0500 - 6 weeks ago

Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma, Ltd. Investors

Tue, 17 Feb 2026 12:59:00 -0500 - 6 weeks ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM

Tue, 17 Feb 2026 09:41:00 -0500 - 6 weeks ago

Portnoy Law Firm Announces Class Action on Behalf of Quantum Corporation Investors

Thu, 12 Feb 2026 16:02:00 -0500 - 7 weeks ago

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM

Tue, 03 Feb 2026 13:12:00 -0500 - 2 months ago

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM

Mon, 02 Feb 2026 10:46:00 -0500 - 2 months ago

Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma Ltd. Investors

Tue, 27 Jan 2026 13:42:00 -0500 - 2 months ago

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM

Dec 23, 2025, 8:00 AM EST - 3 months ago

Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)

Mon, 22 Dec 2025 09:00:00 -0500 - 3 months ago

World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares

Dec 10, 2025, 8:00 PM EST - 4 months ago

Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update

Nov 27, 2025, 4:00 PM EST - 4 months ago

Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada's Largest Banks, CIBC and RBC

Nov 26, 2025, 9:30 AM EST - 4 months ago

Quantum Biopharma's USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5

Nov 7, 2025, 7:00 AM EST - 5 months ago

Quantum Biopharma Reports Strong Third Quarter Results Maintaining ‘No Going Concern' Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio

Oct 31, 2025, 7:51 PM EDT - 5 months ago

Quantum BioPharma Ltd. Provides Corporate Update

Oct 29, 2025, 9:00 PM EDT - 5 months ago

Quantum BioPharma Ltd. Announces Corporate Updates

Oct 23, 2025, 8:15 AM EDT - 5 months ago

Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication

Oct 20, 2025, 8:30 AM EDT - 5 months ago

Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend

Oct 14, 2025, 8:15 AM EDT - 6 months ago

Quantum BioPharma Ltd. Responds to Vague and Misleading Allegations by The Schall Law Firm and DJS Law Group

Oct 9, 2025, 6:00 PM EDT - 6 months ago

Quantum BioPharma Ltd. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QNTM

Oct 9, 2025, 5:40 PM EDT - 6 months ago

QNTM Investors Have Opportunity to Join Quantum BioPharma Ltd. Fraud Investigation with the Schall Law Firm

Oct 8, 2025, 8:00 AM EDT - 6 months ago

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Oct 7, 2025, 11:00 AM EDT - 6 months ago

Quantum BioPharma: Engineering the Digital Balance Sheet in Life Sciences A Vanderbilt Report View

Oct 3, 2025, 7:00 AM EDT - 6 months ago

Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case

Oct 2, 2025, 7:57 AM EDT - 6 months ago

Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial

Oct 1, 2025, 7:50 AM EDT - 6 months ago

Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials

Sep 29, 2025, 7:40 AM EDT - 6 months ago

Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders

Sep 26, 2025, 8:00 PM EDT - 6 months ago

Quantum BioPharma Announces Corporate Updates

Sep 24, 2025, 8:30 AM EDT - 6 months ago

Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar and Q&A Session on Wednesday, October 1, 2025

Sep 18, 2025, 8:10 AM EDT - 7 months ago

Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity™, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance

Sep 12, 2025, 7:50 AM EDT - 7 months ago

Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT

Sep 10, 2025, 7:00 AM EDT - 7 months ago

Kingswood Capital Partners Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$45 Price Target

Aug 11, 2025, 6:32 PM EDT - 8 months ago

Quantum BioPharma Announces Update to Previously Announced Private Placement

Aug 11, 2025, 7:40 AM EDT - 8 months ago

Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial

Aug 8, 2025, 8:00 AM EDT - 8 months ago

Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients

Aug 7, 2025, 7:00 AM EDT - 8 months ago

Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of date of filing, and Near Elimination of Debt

Aug 5, 2025, 7:34 AM EDT - 8 months ago

Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)

Aug 4, 2025, 7:33 AM EDT - 8 months ago

Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing

Jul 31, 2025, 7:24 AM EDT - 8 months ago

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Commences Reg D Capital Raise Campaign to Fund Growth and Possible IPO

Jul 30, 2025, 4:00 PM EDT - 8 months ago

Quantum BioPharma Shares' Rollercoaster Day: What's Going On?

Jul 22, 2025, 7:00 AM EDT - 9 months ago

Quantum BioPharma Makes Strategic Investment in GameStop Corp.

GME

Jun 27, 2025, 4:30 PM EDT - 9 months ago

Quantum BioPharma Announces Private Placement

Jun 26, 2025, 7:30 AM EDT - 10 months ago

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering

Jun 18, 2025, 9:19 AM EDT - 10 months ago

Singular Research Reports on Quantum BioPharma Ltd.'s Strategic Advances and Pipeline Progress

Jun 17, 2025, 8:00 AM EDT - 10 months ago

Quantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General Hospital

Jun 13, 2025, 7:00 AM EDT - 10 months ago

Quantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement Proceeds

Jun 3, 2025, 7:50 AM EDT - 10 months ago

Quantum BioPharma Clarifies It Has Not Changed Its Name

Jun 2, 2025, 1:47 PM EDT - 10 months ago

iNGENū CRO Partners with Quantum BioPharma to Launch Pioneering Australian Clinical Trial for Chronic Nociplastic Pain in MCAS Patients

May 30, 2025, 7:00 AM EDT - 11 months ago

Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari

May 29, 2025, 7:30 AM EDT - 11 months ago

Quantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc.

May 28, 2025, 8:00 AM EDT - 11 months ago

Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome

May 20, 2025, 7:30 AM EDT - 11 months ago

Quantum Biopharma Announces Signing of an Agreement with a Global Pharmaceutical Contract Research Organization to Prepare an IND (Investigational New Drug) Application Package for Lucid-21-302 (Lucid-MS), A First-In-Class Treatment for Multiple Sclerosis

Cons228 Apr. 2 at 8:28 PM

$QNTM thank you, shorts, for confirming that the latest developments in the lawsuit will be massive trouble for you

0 · Reply

focafoca99 Apr. 2 at 7:53 PM

$QNTM says a federal court largely denied the defendants' joint motion to dismiss its $700 million market-manipulation case against CIBC and RBC.

0 · Reply

DzNutz68 Apr. 2 at 2:38 PM

$QNTM these guys shilling are caught short. Fun to watch the panic.

0 · Reply

Rambler1111 Apr. 2 at 1:46 PM

$QNTM

0 · Reply

FickleFin Apr. 2 at 1:25 PM

1 · Reply

TheRealBullz Apr. 2 at 1:03 PM

1 · Reply

Stock_Catcher Apr. 2 at 12:30 PM

0 · Reply

FickleFin Apr. 2 at 11:21 AM

$QNTM $GNS $GME 🤦🤦🤦

1 · Reply

FickleFin Apr. 2 at 11:19 AM

0 · Reply

DzNutz68 Apr. 2 at 3:59 AM

$QNTM 💪💪💪💪👍👍👍👍👍🔥🔥🔥🔥🔥lets go

0 · Reply

DzNutz68 Apr. 2 at 3:55 AM

$QNTM lets go

0 · Reply

ZacksResearch Apr. 1 at 5:09 PM

$QNTM just hit a major FDA milestone — but the real move could be what comes next 👀 The company submitted its IND for Lucid-MS, a first-in-class MS drug targeting demyelination, with Phase 2 planned as soon as FDA clearance hits (anticipated Q2 2026). Phase 1 already showed it was safe & well-tolerated — a key early signal. With a projected $38B MS market by 2030 and a differentiated approach vs. immune-focused therapies, this is a high-stakes catalyst window. See what Wall Street expects next 👉 https://www.zacks.com/stock/research/QNTM/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-37624&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_37624

1 · Reply

FickleFin Apr. 1 at 2:42 PM

$QNTM $GNS its April you fools. 🤡

1 · Reply

Wearewhowethought Apr. 1 at 2:36 PM

$GNS $QNTM the mid day moves thar quantum js making are tje clear signs of a violent algo looking to get out of a short position and create crazy volatility to do so

1 · Reply

Wearewhowethought Apr. 1 at 2:25 PM

$GNS $QNTM

0 · Reply

EdwardTeach Apr. 1 at 1:49 PM

$CYCN $UCAR $RENX $UGRO $QNTM As of April 1, 2026, the book value per share for RenX Enterprises Corp. (RENX) is approximately $7.45.....glta

0 · Reply

Stock_Catcher Apr. 1 at 1:47 PM

Crazy Day Today for the Team on Stocks 📈 $CYCN towards 400% $UCAR 105% $RENX 75% $UGRO 23.50 to 26.39 $QNTM 25% https://www.youtube.com/channel/UCwfLAT9kO2JU-BhoYxGDnrA/join

0 · Reply

Rambler1111 Apr. 1 at 1:46 PM

$QNTM

0 · Reply

sigmalabrador Apr. 1 at 12:59 PM

$QNTM The fry cook at McDonalds earns more revenue than $QNTM. Seriously, I see zero revenue? Also, using the company cash and pouring it into crypto at much higher prices doesn't look like a genius move now. On the positive side, the company is boasting that they didn't have to issue a going concern note in their filings. There are much better prospects in biotech than this dog.

0 · Reply

Wearewhowethought Apr. 1 at 12:29 PM

$GNS $QNTM

0 · Reply

Ronin275 Apr. 1 at 12:14 PM

$QNTM https://feeds.issuerdirect.com/news-release.html?newsid=4855198640190846&symbol=QNTM

0 · Reply

Market Cap	16.83M
Revenue (ttm)	0.00
Net Income (ttm)	-26.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	443,200
Avg Vol	348,388
Day's Range	N/A - N/A
Shares Out	3.82M
Stochastic %K	42%
Beta	0.12
Analysts	Sell
Price Target	$35.50